Covid-19 Kajian Covid-19 | Pesakit COVID-19 tanpa gejala paling cepat hilang antibodi

CG Sponsors




mazri_2008

CG Top Poster Club
Joined
Nov 9, 2008
Messages
47,848
Reaction score
3,887
Points
201

Results from trials involving three different coronavirus vaccines released, all showing positive results, with evidence the vaccines can produce immune responses that would be expected to protect people against infection.

They all also appeared to be safe, although it will take studies with more people to show how safe they really are and whether they can prevent infection.

Early results of a closely watched Phase 1/2 trial published in The Lancet suggest a coronavirus vaccine developed by the University of Oxford and AstraZeneca is safe and induces an immune response. However, researchers stressed more study is needed to know whether the vaccine protects people against the virus.

Phase 2 results for one vaccine candidate made by Chinese company CanSino Biologics were also published in the medical journal The Lancet and early results from Phase 1/2 trials of the vaccine made by Pfizer and BioNTech were released in a pre-print paper that has not yet been peer-reviewed.

The Oxford vaccine prompted an antibody response within 28 days and a T-cell response within 14 days, according to the results published Monday. Neutralizing antibodies -- so-called because they can neutralize the virus -- were detected in most participants after one shot, and in all of them after two.

That's good news, researchers said. "The immune system has two ways of finding and attacking pathogens -- antibody and T cell responses. This vaccine is intended to induce both, so it can attack the virus when it's circulating in the body, as well as attacking infected cells," University of Oxford pediatrician Dr. Andrew Pollard, the study's lead author, said in a statement.

"We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period. However, we need more research before we can confirm the vaccine effectively protects against SARS-CoV-2 infection, and for how long any protection lasts."

It's also not clear how well the vaccine would perform in older people who are more at risk of severe disease from Covid-19.
 
Sponsored Post

mazri_2008

CG Top Poster Club
Joined
Nov 9, 2008
Messages
47,848
Reaction score
3,887
Points
201
Study: Having antibodies does not mean you're immune to COVID-19


 

mazri_2008

CG Top Poster Club
Joined
Nov 9, 2008
Messages
47,848
Reaction score
3,887
Points
201
Kids over age 10 spread COVID-19 as much as adults: study
 

mazri_2008

CG Top Poster Club
Joined
Nov 9, 2008
Messages
47,848
Reaction score
3,887
Points
201
Coronavirus Update: New Study Says People Are More Likely To Contract COVID-19 Inside Home!
 

mazri_2008

CG Top Poster Club
Joined
Nov 9, 2008
Messages
47,848
Reaction score
3,887
Points
201

A significant number of patients who've had COVID-19 report lingering and persistent symptoms 2 months or longer after their initial diagnosis.

Dr. Seheult of https://www.medcram.com discusses the data we have on COVID-19 "long haulers" including a recent study published in JAMA that showed that only 12.6% of patients hospitalized with COVID-19 reported being back to their baseline at about 60 days post-infection. (This video was recorded July 23, 2020).
 

mazri_2008

CG Top Poster Club
Joined
Nov 9, 2008
Messages
47,848
Reaction score
3,887
Points
201
COVID-19 Severity - Study Reveals Cellular Behavior


 

mazri_2008

CG Top Poster Club
Joined
Nov 9, 2008
Messages
47,848
Reaction score
3,887
Points
201
Penyelidik Singapura temui varian baharu COVID-19

SINGAPURA: Kumpulan penyelidik di Singapura berjaya menemui varian atau jenis baharu COVID-19 yang mengakibatkan jangkitan kurang serius, menurut laporan jurnal perubatan The Lancet.

Mereka mendapati pesakit yang dijangkiti dengan varian itu memberi tindak balas lebih baik terhadap rawatan berbanding mereka yang dijangkiti virus varian asal.

Kumpulan penyelidik itu, termasuk dari Pusat Penyakit Berjangkit Kebangsaan (NCID) dan Sekolah Perubatan Duke-NUS, berkata penemuan itu berpotensi untuk pembangunan vaksin atau kaedah rawatan lebih berkesan bagi pesakit COVID-19.

Mengikut laporan pada Mac lalu, varian sama ditemui pada lapan pesakit yang dimasukkan ke hospital di Singapura dan virus dengan mutasi pada bahagian dikenali sebagai ORF8 itu sudah wujud sekurang-kurangnya selama empat minggu.

Pakar penyakit berjangkit dari Sekolah Kesihatan Awam Saw Swee Hock NUS, Prof Madya Hsu Li Yang, berkata mutasi akan terus berlaku terhadap virus COVID-19 selagi penularan masih berlaku.

"Namun, keupayaan virus ini untuk merebak dengan lebih mudah, menjadi lebih atau kurang berbahaya, jarang berlaku," katanya.

Sekumpulan pakar juga mendapati mutasi virus itu berlaku secara berterusan dan ia menjadi rutin atau proses semula jadi kehidupan virus.

Walaupun proses mutasi boleh menyebabkan virus menjadi lebih ganas atau sebaliknya, perubahan yang berlaku lazimnya tidak ketara. - AGENSI
 

Penbiru

CG Top Poster Club
Joined
Jan 12, 2008
Messages
20,437
Reaction score
1,947
Points
201
geng anti vaksin kata Covid19 ni tak mujud pun....saja je dibuat mcm penyakit sebab nak control manusia....ini semua agenda Dajjal kata mereka..so mereka tolak bab pakai mask....PKP tak boleh keluar rumah semua...mereka tentang semua ni...anak pun mereka tak nak vaksin...siapa vaksinkan kalau mereka tak benar mreka akan dakwa....tak tau lah aku
 

mazri_2008

CG Top Poster Club
Joined
Nov 9, 2008
Messages
47,848
Reaction score
3,887
Points
201
New Study Found Heartburn Drug Could Improve COVID-19 Outcomes
 

mazri_2008

CG Top Poster Club
Joined
Nov 9, 2008
Messages
47,848
Reaction score
3,887
Points
201

New findings warn of higher risk in airborne coronavirus transmissions | COVID-19 Special
 
Sponsored Post
Top
Log in Register